Wind Patterns Could Complicate Hemp Cross-Pollination Management
New study links seasonal wind patterns to hemp pollen spread, challenging fixed isolation distances and urging dynamic, risk-based cross-pollination management.
Articles
CBD Shows Antidepressant Potential, but Clinical Evidence Remains Limited
Explore what current research says about CBD as a potential antidepressant, the limits of clinical evidence, safety cautions, and what trials still need to show
Cannabis Legalization and Opioid Deaths: What the Evidence Shows
Does legal cannabis reduce opioid deaths? New evidence shows an association, not proof—plus mixed findings across states. Explore what this means.
Medical Marijuana Legalization Was Not Linked to More Tolerant Views of Cannabis-Impaired Driving
Does medical marijuana legalization change attitudes toward driving after cannabis use? A 2024 study uses DAMU metrics to explore policy effects and norms.
Budtenders’ Medical Cannabis Role Depends on Trust, Training and Clear Boundaries
Discover how budtenders shape medical cannabis care—why trust, training, and clear boundaries matter for safe guidance and appropriate referrals.
Kentucky’s Medical Cannabis Program: What Patients Need to Know
Unlock Kentucky's medical cannabis program: who qualifies, how to apply, what's legal, and the evidence guiding patients through a regulated path.
Cannabigerol Research Points to Broad Therapeutic Potential
Can cannabigerol (CBG) meet its promise? Preclinical hints on pain, inflammation, neuroprotection, metabolism and cancer—why human trials matter.
Why “Indica” and “Sativa” Are Poor Guides to Cannabis Effects
Discover why Indica and Sativa labels don’t reliably predict cannabis effects; learn how cannabinoids, terpenes, dosage, and biology shape your experience.
Adding Cannabis to State Drug-Tracking Systems Was Linked to Fewer High-Risk Prescriptions
Adding cannabis data to state PDMPs reduced high-risk prescriptions, but a 2024 study cautions it doesn’t prove safer outcomes or patient access changes.
FDA Clears Phase 2 Trial Testing Inhaled Cannabis for PTSD in Veterans
FDA clears phase 2 trial testing inhaled cannabis for PTSD in veterans—could real-world dosing reveal benefits or risks, as researchers seek clearer answers.